

IPW

Please Direct All Correspondence to Customer Number **45,311**

**TRANSMITTAL LETTER**  
**INFORMATION DISCLOSURE STATEMENT**


Applicant : Jessouroun et al.  
App. No : 10/566,898  
Filed : February 1, 2006  
For : PROCESS FOR PREPARING  
POLYSACCHARIDE-PROTEIN  
CONJUGATE VACCINES  
Examiner : Unknown  
Art Unit : 1645

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Mail Stop: Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

August 30, 2006

(Date)

  
Nancy W. Vensko, Reg. No. 36,298

**Mail Stop Amendment**

Commissioner for Patents

P.O. Box 1450


Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement and PTO/SB/08 equivalent listing references for consideration:
- (X) Listing 10 references.
  - (X) Enclosing 9 references.
- (X) Return prepaid postcard.


The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.

  
Nancy W. Vensko  
Registration No. 36,298  
Attorney of Record  
Customer No. 45,311  
(805) 547-5580

PA-125

2865567:vr  
082306

3



## INFORMATION DISCLOSURE STATEMENT

Applicant : Jessouroun et al.  
App. No : 10/566,898  
Filed : February 1, 2006  
For : PROCESS FOR PREPARING  
POLYSACCHARIDE-PROTEIN  
CONJUGATE VACCINES  
Examiner : Unknown  
Art Unit : 1645

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 10 references to be considered by the Examiner. Also enclosed are 9 foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement. Please note the relevance of the French-language reference (Mulard) is that it is cited in the International Search Report from PCT priority application serial no. PCT/US2004/026431.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required. If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.


Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 8/30/06

By: 

Nancy W. Vensko  
Registration No. 36,298  
Attorney of Record  
Customer No. 45,311  
(805) 547-5580



<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Multiple sheets used when necessary)	Application No.	10/566,898
	Filing Date	February 1, 2006
	First Named Inventor	Jessouroun, Ellen
	Art Unit	1645
	Examiner	Unknown
SHEET 1 OF 1	Attorney Docket No.	NIH275.001NP2

## U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	4,356,170 A	10-26-1982	Jennings et al.	
	2	WO 2005/014037 A2, US 10/566,899 (National Phase of the above PCT application)	02-17-2005	The Government of the United States of America	

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>1</sup>

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
	3	BARTOLONI, A. et al. 1995 "Immunogenicity of meningococcal B polysaccharide conjugated to tetanus toxoid or CRM197 via adipic acid dihydrazide" <i>Vaccine</i> 13:463-470.	
	4	GUO, Z. and Jennings, H. 2001 "Protein-polysaccharide conjugation" In <u>Methods in Molecular Medicine, Meningococcal Vaccines: Methods and Protocols</u> , Eds. Pollard, A.J. and Maiden, M.C.J., Humana Press Inc., Totowa, N.J. 66:49-54.	
	5	JENNINGS, H. and Lugowski, C. 1981 "Immunochemistry of groups A, B, and C meningococcal polysaccharide-tetanus toxoid conjugates" <i>J. Immunol.</i> 127:1011-1018	
	6	KONADU, E. et al. 2000 "Phase 1 and 2 studies of <i>Salmonella enterica</i> serovar <i>Paratyphi</i> A O-specific polysaccharide-tetanus toxoid conjugates in adults, teenagers, and 2- to 4-year-old children in Vietnam" <i>Infect. Immun.</i> 68:1529-1534.	
	7	LEE, C.-J. 2002 "Quality control of polyvalent pneumococcal polysaccharide-protein conjugate vaccine by nephelometry" <i>Biologicals</i> 30:97-103.	
	8	LEES, A. et al. 1996 "Activation of soluble polysaccharides with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate for use in protein-polysaccharide conjugate vaccines and immunological reagents" <i>Vaccine</i> 14:190-198.	
	9	MULARD, L. et al. 2002 "Vaccins polysidiques" <i>Ann. L'Institut Pasteur Act.</i> 12 :37-54.	
	10	SHAFFER, D. et al. 2000 "Activation of soluble polysaccharides with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate (CDAP) for use in protein-polysaccharide conjugate vaccines and immunological reagents. II. Selective crosslinking of proteins to CDAP-activated polysaccharides" <i>Vaccine</i> 18:1273-1281.	

2786447  
072706

Examiner Signature	Date Considered
--------------------	-----------------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.